Loading...
Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
Weberpals, J. Oza, A. Lorusso, D. Scambia, G. Aghajanian, C. Oaknin, A. Dean, A. Colombo, N. Clamp, Andrew R Leary, A.
Weberpals, J.
Oza, A.
Lorusso, D.
Scambia, G.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Clamp, Andrew R
Leary, A.
Citations
Altmetric:
Abstract
Authors
Weberpals, J.
Oza, A.
Lorusso, D.
Scambia, G.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Clamp, Andrew R
Leary, A.
Holloway, R. W.
Gancedo, M. A.
Fong, P. C.
Goh, J. C.
O'Malley, D. M.
Armstrong, D. K.
Banerjee, S.
Garcia-Donas, J.
Swisher, E. M.
Cameron, T.
Maloney, L.
Goble, S.
Coleman, R. L.
Ledermann, J. A.
Oza, A.
Lorusso, D.
Scambia, G.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Clamp, Andrew R
Leary, A.
Holloway, R. W.
Gancedo, M. A.
Fong, P. C.
Goh, J. C.
O'Malley, D. M.
Armstrong, D. K.
Banerjee, S.
Garcia-Donas, J.
Swisher, E. M.
Cameron, T.
Maloney, L.
Goble, S.
Coleman, R. L.
Ledermann, J. A.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 845.02 KB
Keywords
Type
Meetings and Proceedings
Citation
Weberpals J, Oza A, Lorusso D, Scambia G, Aghajanian C, Oaknin A, et al. Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations. International Journal of Gynecological Cancer. 2020;30:A2-A3.